Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

Deborah Gleeson; James Scheibner; Dianne Nicol

doi:10.5694/mja2.51990

Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

Deborah Gleeson
, James Scheibner
, Dianne Nicol

College of Business, Government and Law

Research output: Contribution to journal › Comment/debate

2 Citations (Scopus)

50 Downloads (Pure)

Abstract

"The Australian Government should review its position and support intellectual property waivers in the pandemic accord"

Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...

Original language	English
Pages (from-to)	46-48
Number of pages	3
Journal	Medical Journal of Australia
Volume	219
Issue number	2
Early online date	11 Jun 2023
DOIs	https://doi.org/10.5694/mja2.51990
Publication status	Published - Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Global health
Health policy
Intellectual property
Pharmaceuticals
Public health
World Health Organization

Access to Document

10.5694/mja2.51990Licence: CC BY-NC-ND

Final published versionFinal published version, 176 KBLicence: CC BY-NC-ND

Cite this

@article{86226ae651fa4116bcb567fb98f60f25,

title = "Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support",

abstract = "{"}The Australian Government should review its position and support intellectual property waivers in the pandemic accord{"} Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26\% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe \& Dohme)...",

keywords = "COVID-19, Global health, Health policy, Intellectual property, Pharmaceuticals, Public health, World Health Organization",

author = "Deborah Gleeson and James Scheibner and Dianne Nicol",

year = "2023",

month = jul,

doi = "10.5694/mja2.51990",

language = "English",

volume = "219",

pages = "46--48",

journal = "Medical Journal of Australia",

issn = "1326-5377",

publisher = "John Wiley \& Sons, Inc",

number = "2",

}

TY - JOUR

T1 - Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

AU - Gleeson, Deborah

AU - Scheibner, James

AU - Nicol, Dianne

PY - 2023/7

Y1 - 2023/7

N2 - "The Australian Government should review its position and support intellectual property waivers in the pandemic accord" Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...

AB - "The Australian Government should review its position and support intellectual property waivers in the pandemic accord" Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...

KW - COVID-19

KW - Global health

KW - Health policy

KW - Intellectual property

KW - Pharmaceuticals

KW - Public health

KW - World Health Organization

UR - https://www.scopus.com/pages/publications/85161427478

U2 - 10.5694/mja2.51990

DO - 10.5694/mja2.51990

M3 - Comment/debate

SN - 1326-5377

VL - 219

SP - 46

EP - 48

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 2

ER -

Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this